NC-PERCONA
20.8.2024 14:31:27 CEST | Business Wire | Press release
Percona, a global leader in enterprise-grade open source database software and services, today announced the addition of two preeminent technology business leaders – John Newton, Co-Founder of Alfresco and Documentum, and Rob Young, a veteran of the open source software ecosystem – as independent directors to its board. The appointments expand the wealth of business strategy, industry expertise and strategic counsel the Percona board offers CEO Ann Schlemmer and her leadership team.
John Newton brings over 40 years of experience in the enterprise software industry, having played a pivotal role in the development and success of numerous companies. A serial entrepreneur, John co-founded Documentum, which was acquired by EMC in 2003, and Alfresco, an open source platform for information management, which had a successful exit with its sale to Hyland Software in 2020. John began his career as one of the founding engineers at Ingres Corporation, where he led the development of their database management system. His innovative contributions to data and information management have earned him several prestigious awards, including recognition as a Technology Pioneer at the World Economic Forum in Davos in 2006 and the Award of Merit from the Association for Intelligent Information Management (AIIM) in 2023. John holds a BS in Electrical Engineering and Computer Science from the University of California, Berkeley, and has served on the boards of several leading companies, including Alfresco, Wideworks, and AIIM.
Rob Young is a seasoned business and technology executive with four decades of experience in building and delivering enterprise solutions through an open source development and delivery model. During his career, Rob has held key technical and leadership positions across various industries, including finance, transportation, healthcare, public utilities, and commercial software and services. Rob has been a driving force in establishing open source software as a trusted foundation for digital transformation. He was instrumental in developing growth strategies and business models focused on value-added differentiation and customer satisfaction in numerous strategic roles at MySQL AB, MongoDB, Percona, RedHat, and DigitalOcean. Notably, while with MySQL AB, Rob led the design, development, and delivery of MySQL Enterprise, which quadrupled the company's revenue in just two years and culminated in a $1 billion acquisition by Sun Microsystems. Rob holds a Bachelor of Science in Economics and Math from the University of Louisville and resides in Louisville, KY.
“We are honored to welcome John Newton and Rob Young to our board,” said Ann Schlemmer, CEO of Percona. “Their extensive experience and deep understanding of the industry will be invaluable as we continue to innovate and deliver world-class solutions to our customers. Their leadership and vision will be crucial as we navigate the opportunities and challenges ahead, ensuring we maintain the highest standards of corporate governance.”
These appointments come at a pivotal time for Percona as the company reaffirms its commitment to cloud-native development with the introduction of Percona Everest and expands its footprint into the Redis ecosystem through its involvement with the Linux Foundation’s Valkey Project. With the addition of John Newton and Rob Young, Percona is well-positioned to accelerate growth and continue its mission of empowering enterprises with robust, reliable, and scalable open source database solutions.
About Percona
Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available. Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815431864/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom